MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA
MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA Merck (NYSE: MRK), known…
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a…
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human…
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile…
CVS Pharmacy introduces new universal tools collection from one+other
CVS Pharmacy introduces new universal tools collection from one+other Today, on International Self-Care Day, CVS Pharmacy® is expanding its one+other assortment with the new inclusively designed Universal Tools collection to…
New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today…
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility Pfizer Inc. (NYSE: PFE) today announced the company’s immediate efforts to provide relief and repair the damage caused to…
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S. Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million…
New global action plan on epilepsy and other neurological disorders published
New global action plan on epilepsy and other neurological disorders published WHO’s Intersectoral Global Action Plan (IGAP) on epilepsy and other neurological disorders, published today in all six UN languages, sets out…
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental…
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) AbbVie (NYSE: ABBV) today announced the European Medicines Agency’s (EMA)…
Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs
Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create…